Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Xencor, Inc.
Xencor, Inc.
Hoffmann-La Roche
Akeso
Hoffmann-La Roche
Thomas Jefferson University
University of Michigan Rogel Cancer Center
University of Pittsburgh
Mario Negri Institute for Pharmacological Research
Bio-Thera Solutions
University of Kentucky
Sanofi
BerGenBio ASA
Sanofi
Jiangsu HengRui Medicine Co., Ltd.
ImmunoGenesis
Bristol-Myers Squibb
Fundación GECP
Checkpoint Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center